Recombinant Human Bone Morphogenetic Protein-2 for Spinal Surgery and Treatment of Open Tibial Fractures

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date:	February 16, 2005
Recommendation:	This topic was reviewed by the California Technology Assessment Forum on February 16, 2005. It was recommended that rhBMP-2 carried on a type 1 collagen sponge used in conjunction with an FDA approved device for the treatment of patients undergoing single level anterior lumbar interbody spinal fusion for symptomatic single level degenerative disease at L4-S1 of at least six months duration that has not responded to non-operative treatments meets CTAF criteria. All other uses of rhBMP-2 including its use in cervical spinal fusions and for treatment of open tibial fracture do not meet CTAF criteria.
Decision:	Does Meet CTAF Criteria
Full Assessment:	Download (PDF)

Search Assessments